INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021

LA JOLLA, Calif, May 24, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that RJ Tesi, MD, chief executive officer, has been invited to present at Alzheimer Disease Panel, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday May 26th, 2021.

INmune Bio will participate in a panel discussion led by Dr. Jason McCarthy, Maxim’s Senior Managing Director of Biotechnology Equity Research, along with other voices in the healthcare industry. Topics will include recent data regarding donanemab and the approaching June 7th Prescription Drug User Free Act (PDUFA) action date for aducanumab.

Please join us May 26th at 11:00 am ET for a panel discussion on exciting topics in AD drug development. Participating companies included Cassava Sciences (SAVA), Vivoryon Therapeutics (VVY), Annovis Bio (ANVS), Cyclo Therapeutics (CYTH) and INmune Bio (INMB). Moderated by Jason McCarthy, Ph.D., Head of Biotechnology Research at Maxim Group LLC.

To access the panel discussion, please RSVP

Webinar Details:

• Panel Session Title: Alzheimer Disease Panel
• Date and Time:  Wednesday May 26th, 11:00 a.m. Eastern time (8:00 a.m. Pacific time)
• Presented by: Maxim Group LLC | Hosted by: M-Vest
• Moderated by: Dr. Jason McCarthy

Click Here to reserve your seat
About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and Treatment Resistant Depression (XPro1595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

Information about Forward-Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com

Investor Contact:
Chuck Padala
LifeSci Advisors
(646) 627-8390
chuck@lifesciadvisors.com